[go: up one dir, main page]

WO2016094341A8 - Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer - Google Patents

Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer Download PDF

Info

Publication number
WO2016094341A8
WO2016094341A8 PCT/US2015/064379 US2015064379W WO2016094341A8 WO 2016094341 A8 WO2016094341 A8 WO 2016094341A8 US 2015064379 W US2015064379 W US 2015064379W WO 2016094341 A8 WO2016094341 A8 WO 2016094341A8
Authority
WO
WIPO (PCT)
Prior art keywords
ganetespib
taxane
breast cancer
combination therapy
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/064379
Other languages
French (fr)
Other versions
WO2016094341A1 (en
Inventor
David Proia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of WO2016094341A1 publication Critical patent/WO2016094341A1/en
Publication of WO2016094341A8 publication Critical patent/WO2016094341A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein is a combination therapy comprising ganetespib, a taxane, and a monoclonal antibody that interferes with the HER2/neu receptor, pharmaceutical compositions thereof, and methods for use, such as to treat humans with HER2-positive breast cancer (BC).
PCT/US2015/064379 2014-12-08 2015-12-08 Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer Ceased WO2016094341A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088853P 2014-12-08 2014-12-08
US62/088,853 2014-12-08

Publications (2)

Publication Number Publication Date
WO2016094341A1 WO2016094341A1 (en) 2016-06-16
WO2016094341A8 true WO2016094341A8 (en) 2016-09-15

Family

ID=55130022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/064379 Ceased WO2016094341A1 (en) 2014-12-08 2015-12-08 Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer

Country Status (1)

Country Link
WO (1) WO2016094341A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012155063A1 (en) * 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
WO2013055874A2 (en) * 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
WO2013170182A1 (en) * 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound

Also Published As

Publication number Publication date
WO2016094341A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
MX2023014569A (en) Anti-sirp alpha antibodies.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MY189536A (en) Subcutaneous her2 antibody formulations
MX2022014914A (en) Glycan-interacting compounds and methods of use.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2022008523A (en) Glycan-interacting compounds and methods of use.
PH12017502270A1 (en) Combination therapy for the treatment of cancer
MX2018014175A (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
PH12016502518A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
TN2015000396A1 (en) Antibody drug conjugates
TN2017000024A1 (en) Anti-tigit antibodies.
MX2017004715A (en) Humanized anti-ox40 antibodies and uses thereof.
MA39909A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
IN2014MU00303A (en)
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
IL247436A0 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
HK1255056A1 (en) Anti-cd115 antibodies
HK1251481A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
MX2019001958A (en) Methods of treating crohn's disease with an anti-nkg2d antibody.
HK1250626A1 (en) Combination treatments with seribantumab
MX2017001176A (en) Combination therapy.
MX2020000636A (en) Synthetic proteins and therapeutic uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15823552

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 15823552

Country of ref document: EP

Kind code of ref document: A1